Screener
Gilead Sciences GILD AmBisome — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Trodelvy | 307 | 92 | 57 | 457 | 224 | 96 | 44 | 364 |
| Total Oncology | 468 | 265 | 140 | 873 | 427 | 291 | 131 | 849 |
| Other | ||||||||
| AmBisome | 4 | 47 | 59 | 110 | 7 | 65 | 56 | 129 |
| Other(5) | 22 | 8 | 21 | 51 | 44 | 8 | 21 | 73 |
| Total Other | 26 | 55 | 80 | 161 | 52 | 73 | 77 | 202 |
| Total product sales | 5,601 | 1,155 | 872 | 7,627 | 5,038 | 1,178 | 838 | 7,054 |
| Royalty, contract and other revenues | 2 | 169 | 4 | 176 | 13 | 10 | 4 | 27 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's ambisome — total revenues?
- Gilead Sciences (GILD) reported ambisome — total revenues of $110M in Q2 2026.
- How has Gilead Sciences's ambisome — total revenues changed year-over-year?
- Gilead Sciences's ambisome — total revenues decreased by 14.7% year-over-year, from $129M to $110M.
- What is the long-term trend for Gilead Sciences's ambisome — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's ambisome — total revenues has grown at a -1.5% compound annual growth rate (CAGR), from $540M to $509M.
- What does ambisome — total revenues mean?
- This metric represents the total net sales generated from the AmBisome product line, which is an antifungal medication used to treat serious fungal infections. It reflects the market demand and commercial performance of this specific therapeutic asset within the company's broader infectious disease portfolio. Monitoring this revenue stream helps investors assess the stability and lifecycle maturity of established specialty pharmaceutical products.
Ask your AI about Gilead Sciences's ambisome — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude